Price T Rowe Associates Inc. MD Has $1.03 Billion Position in Repligen Co. (NASDAQ:RGEN)

Price T Rowe Associates Inc. MD grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 11.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,136,054 shares of the biotechnology company's stock after acquiring an additional 743,815 shares during the period. Price T Rowe Associates Inc. MD owned about 12.74% of Repligen worth $1,027,165,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RGEN. Vanguard Group Inc. raised its holdings in Repligen by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after acquiring an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC increased its position in shares of Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after purchasing an additional 122,595 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock valued at $145,508,000 after purchasing an additional 191,439 shares in the last quarter. Conestoga Capital Advisors LLC lifted its position in shares of Repligen by 0.7% during the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock worth $136,395,000 after purchasing an additional 6,872 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in Repligen by 2.5% in the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock worth $83,693,000 after purchasing an additional 14,398 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RGEN. Royal Bank of Canada upped their price target on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. Canaccord Genuity Group lowered their price target on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Finally, TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Repligen has an average rating of "Hold" and an average price target of $176.82.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by insiders.

Repligen Price Performance

Shares of RGEN traded down $0.48 during trading hours on Friday, hitting $144.75. 439,931 shares of the company were exchanged, compared to its average volume of 712,103. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $8.13 billion, a PE ratio of -283.82, a PEG ratio of 4.54 and a beta of 1.27. The firm has a fifty day simple moving average of $139.80 and a 200-day simple moving average of $145.79. Repligen Co. has a one year low of $102.97 and a one year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, sell-side analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.